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The mapping of paediatric vaccination process in the United Kingdom (UK), as a 
precursor of a real-world study, is described. Methods: A targeted review of pub-
licly available information was conducted to gain comprehensive understanding 
of the paediatric vaccination process in the UK. A survey was designed eliciting 
the chronology of vaccination process prior to and on vaccination day, including 
estimates of active health care professional involvement. Face-to-face interviews 
with a nurse were conducted at three general practitioner surgeries routinely 
performing vaccinations. A subsequent follow-up call with each nurse was also 
arranged. Descriptive statistics were generated and preliminary cost calculations 
made. Results: Paediatric vaccination process can be broken down in 6 and 8 
clearly discernible steps prior to and on vaccination day, respectively. Activities 
prior to vaccination day include, among others, inventory, ordering, cold-chain 
management and are typically for multiple subjects. Mean time for those activities, 
recalculated per single vaccination visit, was 6.7 minutes, of which 61% dedicated 
to administrative duties. Activities on vaccination day include, among others, room 
preparation, consultation, vaccine administration. Estimated time per single visit 
totaled 25.4 minutes. Estimated total cost per single vaccine administration, with 
nurse salary cost from PSSRU, was £10.4. Costs may vary substantially depending 
on the level of “on-costs” to nurse’s gross salary. ConClusions: The detailed 
mapping of paediatric vaccination process in the UK identified clearly discernible 
tasks, time estimates, factors impacting variability of time outcomes, and early 
cost estimates. This forms the basis of a real-world T&M study aiming to generate 
robust time and cost outcomes.
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objeCtives: Guidelines for Health Technology Assessment (HTA) and Comparative 
Effectiveness Research (CER) largely focus on pharmaceuticals and only few explic-
itly consider other health care technologies. CER of medical devices (MD) faces some 
challenges that raise questions about how adequate current CER methods account 
for the specific features of MD and how well MD fit in the paradigm of drug HTA. Our 
aim was to identify challenges and gaps in methodology related to specific issues 
of MD. Our comprehensive framework for the evaluation of clinical effectiveness of 
MD includes recommendations for generation of primary data and analyzing and 
synthesizing data in systematic reviews of CER of MD. Methods: We performed a 
targeted literature review for CER methods and specific features of MD. An electronic 
database search was combined with systematic screening of tables of content of 
selected journals in the fields of epidemiology, HTA, statistics, and evidence-based 
medicine, which have a strong focus on methods. Additionally, we screened the 
reference lists of the most relevant papers. Results: More than 200 publications 
about the general evaluation of MD and about specific CER methods were included. 
The MD’s physical mechanism of action, the dynamic development and regulatory 
evidence requirements are the driving features that suggest the increased use of 
certain methods for the evidence generation, finding of information for HTA, data 
analysis and synthesis, and interpretation of results. Rather than following the para-
digms of drug evaluation, MD resemble more the notion of complex interventions. 
Our methodological framework is compatible with the EUnetHTA core model and 
integrates existing recommendations for other complex interventions. The con-
sideration of observational data, operator characteristics, active control trials, and 
decision-analytic modeling are of special importance, as well as the application of 
Bayesian methods. ConClusions: The assessment of the clinical effectiveness of 
MD does require specific, although not necessarily new methods.
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objeCtives: Poor adherence to anti-epileptic drugs has been shown to be the 
most important cause of poorly controlled epilepsy. Furthermore, it is emphasized 
that an increase in quality of life among patients with epilepsy could be reached 
by counseling and treatments aimed at increasing their self-efficacy and thus 
stimulate self-management. However, there is a need for evidence on the effec-
tiveness of such programs, especially within epilepsy care. Therefore, we have 
developed a multi-component intervention (MCI) which combines a self-manage-
ment/education program with e-Health interventions. Hence the overall objec-
tive of this study is to assess the (cost-) effectiveness of a MCI aiming to improve 
self-efficacy in people with epilepsy compared to care as usual. Methods: A 
randomized controlled trial in 2 parallel groups will be conducted to compare 
the MCI intervention with a waiting list control condition in epilepsy patients. 
One hundred eligible epilepsy patients will be recruited from the Kempenhaeghe 
epilepsy center and allocated to intervention or control group. Patients in the 
intervention group will receive an education program of six meetings including 
e-Health intervention and will be followed for 12 months. Patients in the control 
group will be followed for 6 months after which they will be offered to participate 
in the MCI. The study will consist of three parts: 1) a clinical effectiveness study, 
2) a cost-effectiveness study, and 3) a process evaluation. The primary outcome 
will be self-efficacy. Outcome assessments will be done using questionnaires at 
baseline and after 3, 6, 9, and 12 months. Results: N/A. ConClusions: This 
study will determine the (cost-) effectiveness of an MCI intervention to improve 
the self-efficacy of epilepsy in adult patients. The MCI is designed to stimulate 
self-management skills and awareness of epilepsy patients in combination with 
analyses reduce the probability of finding significant results due to chance while 
large numbers of outcome events reduce the overestimation of treatment effects. 
Our analysis finds that a statistically significant gain in OS is an important deci-
sion driver for even the most critical HTA agencies, although the treatment effect 
may still be questioned when the trial is unblinded early. HTA agencies appreciate 
to receive the latest available information (UK, Australia and Germany) and may 
reject the use of oncology drugs when there is too much uncertainty around OS 
estimates to justify the proposed price. It is generally useful to continue data col-
lection and follow-up patients should HTA agencies still request more reliable OS 
estimates for modeling purposes (UK and Australia) or long-term risk-benefit evalu-
ation (France). ConClusions: Payers are aware of the overestimation of effect size 
due to early trial termination and may reject drugs for high uncertainty around OS 
estimates. For adequate responses to requests for more reliable data, it is advised 
to continue data collection and follow-up patients.
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objeCtives: IBS is often a diagnosis of exclusion, with poor diagnosis coding in 
primary care and identification of eligible research participants challenging. We 
present the methodology of an on-going multi-centre, observational, retrospec-
tive research study, designed to overcome the challenges of IBS patient identifica-
tion. Methods: FARSITE, a software tool for identification of research participants 
developed by the Greater Manchester Comprehensive Local Research Network and 
North West eHealth, was used to screen anonymised primary care records for 
potentially eligible patients. Ethical approval reference 13/LO/0692. Search criteria: 
patients aged 18-60; combination READ code symptoms indicative of IBS and pre-
scription of IBS medications 01/01/2009–31/12/2011. GPs at 8 participating practices 
in Salford & Greater Manchester reviewed clinical records of the FARSITE-generated 
list of patients to apply full eligibility criteria for final patient selection. Inclusion 
criteria: medical diagnosis of IBS or meeting ROME III criteria; provision of consent. 
Exclusion Criteria: diagnosis excluding IBS; IBS symptoms secondary to other con-
dition; IBS medications only for non-GI symptoms. Results: FARSITE identified 
1089 (1.3%) patients, of which 297 (27.3%) were eligible. 97 patients consented to 
participation (79% female). Main reasons for non-eligibility were not meeting ROME 
III criteria or IBS excluded by medical opinion. Patients were most commonly coded 
as irritable colon (37%), difficulty defecating (21%), abdominal pain (18%), diarrhoea 
symptoms (14%). Four (4%) patients had a READ code specific for IBS. The median 
(IQR) time from 1st presentation with abdominal symptoms to study eligibility was 
3.98 (0.00-9.04) years. ConClusions: Identification of patients with IBS using READ 
codes is sub-optimal in primary care. A combination search of READ codes with 
symptom and prescription data via FARSITE has enabled potential participants to 
be identified with a reasonable screening failure rate. FARSITE is a valuable research 
tool aiding study feasibility by reducing the need for manual patient identification.
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objeCtives: Patient access to NBS has been greatly influenced by the 2006 
American College of Medical Genetics (ACMG) recommended expansion of NBS. 
ACMG relied largely on a stakeholder survey on 19 attributes of 84 rare conditions. 
The percentage of respondents agreeing to an attribute’s presence for a condition, 
along with its weight, determined attribute score. Sums of scores determined the 
entry point to an algorithm for final recommendations. This research examines 6 
attributes that appear to be associated with the same concept and asks whether 
these are really one (over-weighted) concept. Methods: The ACMG report pro-
vided attribute scores. Six questions addressed test efficiency (simplicity, high 
throughput, cost < $1/condition, multiple analytes/test run, other conditions 
identified/analyte, multiple conditions detected/test). We examined correlations 
between the 6 answers for a given condition across conditions and associations 
with recommendations. Results: After eliminating conditions with missing data, 
78 remained. Pairwise correlations between the 6 answers were high (mean= .85; 
range, .72-.96). Of those conditions (37) scoring at least 75% of the possible points 
on one question (“high throughput”), 79% were recommended as Core conditions 
to be screened and only 8% were Not Recommended. The mean total scores for the 
6 similar questions was 339 (500 possible). Of those (19) scoring 25% or fewer of the 
possible points for that one question, only 3% were Core, 72% Not Recommended 
(mean score:89). ConClusions: The high correlations support the idea that the 
6 similar questions were answered as if they were the same concept, weighting the 
common general attribute very highly. A more systematic approach, say MCDA, 
would likely have eliminated some of these questions with significant consequences 
for ACMG recommendations.
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objeCtives: Time and Motion (T&M) methodology allows quantifying time-
related outcomes for a health care delivery process by disaggregating the process 
in its constituent parts to measure task durations. The design of a T&M study 
requires early process mapping to define the time outcomes to be measured. 
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risk. Automated edit checks of primary data endpoints should be programmed into 
the EDC system prompting data abstractors to revise erroneous data and/or confirm 
data outside of expected ranges at entry. To confirm abstracted data reflect source 
documents (patient medical charts), a second abstractor at the site can re-abstract 
pre-defined critical study variables from patient medical charts for cross-referencing 
for data discrepancies. Site training must be effective to ensure compliance with 
chart abstraction and data quality requirements. ConClusions: Given the fre-
quent incomplete or poor quality medical chart information and the potential for 
human error in data abstraction and entry processes, data quality control methods 
are paramount. Approaches to protocol, CRF and study training materials design 
can positively impact data quality.
ReseaRCh on Methods – Conceptual Papers
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objeCtives: Health technology assessment typically involves consideration of mul-
tiple conflicting criteria. Therefore, trade-offs are required between different objec-
tives such as maximizing health, restricting budget impact, increasing health equity 
and maximizing safety. Methods such as multiple decision criteria analysis (MCDA) 
are therefore increasingly being used to reflect such trade-offs in a transparent 
and consistent manner. Although MCDA can be combined with cost-effectiveness 
analysis it may, however, invalidate results from Value of Information (VOI) analysis 
when it also includes other health-related or cost-related objectives. Methods: In 
two case studies we first applied VOI methods directly and only to cost-effectiveness 
estimates, and then also applied these methods separately to all relevant deci-
sion criteria. In a simulation study on two drugs we calculated the expected value 
of perfect information (EVPI) with drug selection concerning a trade-off between 
cost-effectiveness and drug safety. In a clinical study on the primary prevention of 
cardiovascular disease using improved versus standard risk prediction we calculated 
the EVPI with selection of the best risk prediction strategy concerning a trade-off 
between cost-effectiveness and budget impact. Results: In our simulation study 
we found EVPI estimates per patient based only on cost-effectiveness were up to 
€ -586 lower and € +459 higher compared to EVPI estimates also acknowledging 
the safety criterion, depending on its weight. In our clinical study, the EVPI esti-
mates based only on cost-effectiveness were consistently lower, up to € -540 per 
patient, compared to EVPI estimates also acknowledging the budget impact cri-
terion. ConClusions: When decisions are based not only on cost-effectiveness 
but on other criteria as well, some of which also relate to costs or health effects, 
standard VOI estimates are no longer valid. However, separate application of VOI 
methods to each of the relevant decision criteria is straightforward and can facilitate 
transparent research prioritization in a complex MCDA context.
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The benefits and value of new cancer treatments often focus on the overall survival 
(OS) gains that patients may derive. Trials are typically not long enough to allow 
detailed understanding of OS, and potential benefits must be inferred from benefits 
on progression-free-survival (PFS). This raises questions such as whether early or later 
progression impacts survival, whether the increase in mortality following progression 
is sustained or gradually diffused, and whether a benefit observed on PFS implies a 
benefit in OS. Answering these questions requires an analytical framework in which 
progression and survival can be analyzed together and parameterized to address key 
questions. We propose a statistical modeling framework based on Cox regression and 
time-dependent predictors and effects. A simple formulation of this model would 
include a time-dependent indicator for progression, whose coefficient would meas-
ure the increase in risk of death following the event. This is very limiting, however; 
it assumes that the timing of progression does not matter and that the increase in 
risk of death is sustained indefinitely. A more flexible formulation can be built using 
two descriptors of event: the timing of progression (TP) and time since progression 
(TSP). These can be continuous measures or categorized (e.g., early vs. late TP), as 
appropriate. The coefficient for TP reveals whether later progression is associated 
with higher/lower subsequent mortality, while the coefficient of TSP reflects whether 
and for how long the increase/decrease in mortality is sustained and whether it ever 
returns to the level of patients who had not progressed. The impact of treatment can 
be captured on each of these parameters separately. The proposed framework will 
be illustrated with an example, and extension of the approach to other applications 
(e.g., measuring the impact of a stroke on survival) will be discussed.
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Despite the availability of a large body of research evidence on patient preferences 
for health outcomes and/or health care services, its use in health care policy deci-
sions is limited. This contrasts with the current increasing attention for patient-cen-
the use of e-health interventions.*Both B. F. M. Wijnen and L. A. M. Leenen con-
tributed equally to this work.
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objeCtives: In the absence of secondary sources of health care data, chart review 
studies can result in patient level data repositories including patient characteris-
tics, care patterns, treatment effectiveness and clinical and safety outcomes. Data 
can be used to populate economic evaluations, and value dossiers, and inform 
drug safety assessments. For successful implementation, however, knowledge of 
country-specific ethics and regulatory approval processes is paramount. Methods: 
Operational, ethics and regulatory issues and considerations as well as strategies for 
study success have been summarized in the context of eleven recent multi-national 
chart review case studies. Results: Two of 11 studies also collected data prospec-
tively; two studies were categorized as post authorization safety studies and three 
studies were conducted in peri-approval compassionate use program populations. 
The majority of studies (9) were oncology focused, with two studies focused on 
infectious diseases and opioid-induced constipation. Sample sizes varied from 20 
to 500 patients, the number of countries from 1 to 8, and the number of sites from 4 
to 61. All studies included at least one European country. Across studies, key opera-
tional considerations that impacted the ethical/regulatory approval process were 
ambiguous/amorphous multinational regulatory requirements/guidelines; com-
mercial availability or non-availability of the sponsor product at the time of chart 
abstraction; data collection method(s) (i.e., retrospective vs. hybrid chart review plus 
prospective data collection); country variation in informed consent requirements 
and definitions of personal data; and multinational contractual requirements with 
the participating sites. ConClusions: International chart review studies are an 
effective methodology to resolve data gaps not solved by existing secondary health 
care data sources resulting in tailored, patient-level datasets. Current knowledge of 
the highly variable and evolving global regulatory requirements, as well as the devel-
opment of a risk management plan informed by methodological and operational 
lessons learned at study-outset will facilitate risk mitigation and allow researchers 
to overcome key challenges.
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objeCtives: In addition to study outcome concerns arising from patients lost to 
follow-up (LFU) in pharmacoepidemiology and pharmacovigilance studies, the 
financial impact of LFU can be significant. Our objectives were to estimate cost 
per patient in Non-interventional studies, to identify variables that may affect this 
patient cost, to estimate cost of patient lost to follow-up (LFU), and financial benefits 
that can be expected from LFU minimization through Direct to Patient Contact ser-
vice (DPC). Methods: Analysis of 2013 proposals and budgets submitted to study 
sponsors. Selection criteria: non interventional, prospective, longitudinal patient fol-
low-up, full CRO services. Analysis were performed according to patient sample size, 
study duration, disease category, and different hypothesis for LFU rates. Results: 
1) 20 studies (Domestic, Regional or Global) met all inclusion criteria; 2) Annual 
cost per patient -ranging from € 1,068 to € 4,370- decreases as the study duration 
increases (set-up cost is more diluted in the patient annual cost). But the longer the 
study is the more expensive the overall cost per patient; 3) Mean annual patient cost 
significantly differs according to rarity of disease/population; rarity is an important 
criterion that greatly impacts overall and annual patient cost, especially for study 
lasting more than 1 year. Below 1 year, the cost per patient remains quite similar 
between types of diseases/populations; 4) Cost are more significant in rare diseases 
studies, therefore DPC can provide the best overall cost savings in these populations; 
and 50 The cost savings are depended on the expected rate of patient LFU-with/
without DPC service and the planned patient sample size. ConClusions: Return 
On Investment plays an important role for Sponsors to determine if DPC is valu-
able in a study. The financial investment may be beneficial regardless of the cost to 
insure completion of the patients, thus meeting the scientific study objectives. But 
it could generate cost savings as well.
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objeCtives: Retrospective chart review studies can result in robust naturalistic 
data to inform evaluations of treatment patterns, resource utilization, costs of care, 
clinical outcomes and safety. Data quality control is challenging both as a result of 
poor quality documentation in the usual care medical chart, or as a result of data 
abstraction and data entry processes. Methods: Ten chart review case studies con-
ducted in the United States, Canada and Europe were evaluated to provide recom-
mendations for improving chart review data quality control mechanisms. Results: 
All 10 studies used electronic data capture (EDC) systems. Common lessons learned 
across the studies were that the case report forms (CRFs) should only include neces-
sary data points required to fulfill the analysis. Direct chart-to-EDC data entry and 
remote real-time data quality control is recommended to reduce additional tran-
scription errors that may occur if using paper CRFs. It is important to ensure the EDC 
system includes a cohort-control platform that enables selection of patient cohorts 
(i.e., random selection) and tracking of eligibility screening to reduce selection bias 
